{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59","upperLimit":"88","value":"74"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"To evaluate progression-free survival (24 month estimate)\n\nHematologic progression is defined as 50% increase from nadir, or from baseline (if there was no response) in any ONE OR MORE of the following:\n\n1. Serum M-protein: 50% increase in Serum M protein to a value greater than 0.5 g/dL.\n2. Urine M protein: 50% increase in Urine M protein to a value greater than 200 mg/day (a visible peak must be present)\n3. Free light chain increase of 50% to a value greater than 10 mg/dL","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Isatuximab"}],"paramType":"NUMBER","populationDescription":"35 participants were analyzable","reportingStatus":"POSTED","timeFrame":"From registration to time of confirmed hematologic progression","title":"Progression-free Survival (24 Month Estimate)","type":"SECONDARY","unitOfMeasure":"percentage of paticipants"}